At Risk, SCI, eMCI: The Alphabet Soup of Preclinical and Prodromal Alzheimer Disease

Activity Details
  • Credit Amounts:
    • CNE: 1.20
    • UNTHSC: 1.00
    • Physicians: 1.00
  • Cost: Free
  • Release: May 23, 2018
  • Expires: May 23, 2020
  • Estimated Time to Complete:
    1 Hour(s)
  • System Requirements:
  • Average User Rating:
    ( Ratings)

Faculty

Mary Quiceno Mary Quiceno, MD, FAAN
Associate Professor of Medical Education
TCU/UNTHSC School of Medicine
Fort Worth, Texas

Needs Statement

This presentation will discuss updates in the field on the diagnosis, prognosis and possible therapies for preclinical (cognitively normal adults at risk for Alzheimer Disease) and prodromal (adults with mild cognitive impairment due to Alzheimer disease) Alzheimer disease.

Target Audience

This activity was planned to address the educational needs of physicians, physician assistants, nurse practitioners and nurses.

Objectives

  • Distinguish between the stages of Alzheimer disease (AD) which precede dementia, ie preclinical/at risk/stage 0, subjective cognitive impairment (SCI)/stage 1, and early mild cognitive impairment/prodromal AD/stage 3;
  • Explain the temporal progression and risk factors for progression and treatments for each stage of AD which precedes dementia; and
  • Apply recent research findings to be able to identify patients in these stages of AD

Accreditation

Physicians

The University of North Texas Health Science Center is accredited by the American Osteopathic Association to award continuing medical education to physicians.

The University of North Texas Health Science Center is accredited by the American Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of North Texas Health Science Center has requested that the AOA Council on Continuing Medical Education approve this program for 1 hour of AOA Category 2B CME credits.  Approval is currently pending.

The University of North Texas Health Science Center at Fort Worth designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE

UNT Health Science Center is approved by the California Board of Registered Nursing, Provider # 16274. This activity is approved for 1.20 Contact Hours.

UNTHSC
The University of North Texas Health Science Center certifies this activity for 1.00 hour of participation.

The University of North Texas Health Science Center presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.


ACGME Competencies

  • Medical knowledge

IOM Competencies

  • Employ evidence-based practice

 

Faculty Disclosure

Mary Quiceno, MD discloses she has received honoraria from Adamas and Eli Lilly and receives research support from Eli Lilly.   The UNT Health Science Center INCEDO Staff has nothing to disclose.

This presentation will contain off-label discussion of new clinical trials looking at use of amyloid therapies (monoclonal antibodies and BACE inhibitors).

Acknowledgment

WE-HAIL LogoThis project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number U1QHP287350100. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Health Resources and Services Administration or the U.S. Department of Health and Human Services.

No commercial support was received for this activity.

Additional Information

Data collected as part of this activity may be analyzed as part of educational research to study the effectiveness of interventions. This project is included under UNTHSC IRB protocol #2017-056